SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ANRG -- Anergen -- new CEO big chance ?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tonyt who wrote (61)1/26/1998 12:10:00 PM
From: aknahow  Read Replies (1) of 123
 
While old new, from Jan 15 Sturza letter shows ANRG reduced to hold from buy. The results of its P II RA-AnervaX trials were not robust enough to proceed into Phase III trials. These results were presented back in Nov. at the American College of Rheumatology.

Given the dated nature of the above there may be other reasons for the current decline.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News